• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Analysis of morbid events and risk factors for death after cardiac transplantation.

作者信息

Kirklin J K, Naftel D C, McGiffin D C, McVay R F, Blackstone E H, Karp R B

机构信息

Department of Surgery, University of Alabama, Birmingham School of Medicine 35294.

出版信息

J Am Coll Cardiol. 1988 May;11(5):917-24. doi: 10.1016/s0735-1097(98)90045-6.

DOI:10.1016/s0735-1097(98)90045-6
PMID:3281995
Abstract

Risk factors for death after cardiac transplantation performed at the University of Alabama at Birmingham from January 1981 to July 1985 included (by multivariate analysis) higher calculated preoperative pulmonary vascular resistance (early and constant phases), morphology of cardiomyopathy (versus ischemic heart disease) (constant phase only) and black race (constant phase). Overall actuarial survival was 71% at 1 year and 48% at 3 years (including azathioprine and cyclosporine eras). The hazard function for death was highest immediately after operation and declined rapidly thereafter, merging with a constant phase of risk at about 3 months. The most favorable group for long-term survival was the group of white patients with ischemic heart disease and low pulmonary vascular resistance. When such patients had a pulmonary vascular resistance less than 3 units.m2, the 3 year survival rate exceeded 85%. The most common causes of death were acute rejection (24%) and infection (17%). The risk of infection remained highest during the first several months after any period of augmented immunosuppression.

摘要

相似文献

1
Analysis of morbid events and risk factors for death after cardiac transplantation.
J Am Coll Cardiol. 1988 May;11(5):917-24. doi: 10.1016/s0735-1097(98)90045-6.
2
Pediatric cardiac transplantation. The Stanford experience.小儿心脏移植。斯坦福大学的经验。
Circulation. 1994 Nov;90(5 Pt 2):II51-5.
3
Immunosuppression after heart transplantation: prednisone and cyclosporine with and without azathioprine.心脏移植后的免疫抑制:泼尼松与环孢素联用,以及是否联用硫唑嘌呤。
J Thorac Cardiovasc Surg. 1989 Nov;98(5 Pt 2):951-5.
4
Present expectations in cardiac transplantation.
Ann Thorac Surg. 1987 Jun;43(6):585-90. doi: 10.1016/s0003-4975(10)60227-5.
5
[Pathology of heart transplantation.(Morphological study of 1246 endomyocardial biopsies from 167 transplanted hearts). Causes of early, intermediate, and late deaths].心脏移植病理学。(对167例移植心脏的1246份心内膜心肌活检的形态学研究)。早期、中期和晚期死亡原因
Pathologica. 1999 Apr;91(2):89-100.
6
Heart transplantation--a two-year experience.心脏移植——两年经验
Z Kardiol. 1985;74 Suppl 6:51-8.
7
Cardiac transplantation in children and adolescents.
Circulation. 1987 Nov;76(5 Pt 2):V43-7.
8
Rejection and infection after pediatric cardiac transplantation.
Ann Thorac Surg. 1990 Mar;49(3):385-90. doi: 10.1016/0003-4975(90)90241-w.
9
Long-term results of pediatric heart transplantation.
J Heart Lung Transplant. 1992 Jul-Aug;11(4 Pt 2):S277-81.
10
Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantation.溴隐亭作为心脏移植后环孢素免疫抑制的辅助药物。
Ann Thorac Surg. 1990 Jan;49(1):129-32. doi: 10.1016/0003-4975(90)90370-l.

引用本文的文献

1
Heart transplantation in biventricular congenital heart disease: indications, techniques, and outcomes.双心室先天性心脏病的心脏移植:适应证、技术及结果
Curr Cardiol Rev. 2011 May;7(2):92-101. doi: 10.2174/157340311797484196.
2
Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center.心脏移植患者的个体化全身淋巴照射:单中心 10 年经验。
Radiat Oncol. 2010 Jan 16;5:3. doi: 10.1186/1748-717X-5-3.
3
Impact of animal strain on gene expression in a rat model of acute cardiac rejection.动物品系对大鼠急性心脏排斥反应模型中基因表达的影响。
BMC Genomics. 2009 Jun 24;10:280. doi: 10.1186/1471-2164-10-280.
4
The challenge of rejection and cardiac allograft vasculopathy.排斥反应和心脏移植血管病变的挑战。
Heart Fail Rev. 2001 Sep;6(3):227-40. doi: 10.1023/a:1011414307636.
5
Myocardial revascularization as a therapeutic strategy in the patient with advanced ventricular dysfunction.
Heart Fail Rev. 2001 Sep;6(3):163-75. doi: 10.1023/a:1011416929501.
6
Incidence and prognostic value of electrocardiographic abnormalities after heart transplantation.心脏移植后心电图异常的发生率及预后价值
Clin Cardiol. 1998 Sep;21(9):680-4. doi: 10.1002/clc.4960210914.
7
Mechanisms of transplant right ventricular dysfunction.移植后右心室功能障碍的机制。
Ann Surg. 1995 Jun;221(6):666-75; discussion 675-6. doi: 10.1097/00000658-199506000-00006.
8
Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy.对于慢性缺血性心肌病,应选择冠状动脉血运重建而非心脏移植。
Ann Surg. 1989 Sep;210(3):348-52; discussion 352-4. doi: 10.1097/00000658-198909000-00011.
9
[Therapy of terminal heart failure using heart transplantation].[心脏移植治疗终末期心力衰竭]
Klin Wochenschr. 1991 Aug 16;69(12):495-505. doi: 10.1007/BF01649285.
10
Fall in pulmonary vascular resistance in patients awaiting heart transplantation.等待心脏移植患者的肺血管阻力下降。
Br Heart J. 1992 Oct;68(4):365-8. doi: 10.1136/hrt.68.10.365.